Novartis acquires Arctos Medical to develop gene therapy programme
The Arctos Medical acquisition will expand Novarits’ optogenetics portfolio to bring gene therapies to patients with severe vision loss.
List view / Grid view
The Arctos Medical acquisition will expand Novarits’ optogenetics portfolio to bring gene therapies to patients with severe vision loss.
US Pharmacopeia to collaborate on assessment of analytical methods for adeno-associated viruses (AAVs) to facilitate the development of reference standards.
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.